Kynmobi (Apomorphine Hydrochloride Hemihydrate)

Apomorphine, a dopamine agonist used in Parkinson's disease, is indicated for managing OFF episodes and related motor fluctuations.

• OFF episodes in Parkinson's disease: provides rapid reversal of motor symptoms during periods of reduced dopaminergic response.
• Motor fluctuations in Parkinson's disease: improves on‑time and reduces periods of bradykinesia.
• Adjunct therapy in Parkinson's disease: enhances overall dopaminergic control when combined with other antiparkinsonian agents.

• Apomorphine hydrochloride hemihydrate acts as a non‑selective dopamine receptor agonist, stimulating both D1‑like and D2‑like receptors in the basal ganglia. This direct activation bypasses the need for endogenous dopamine, increasing dopaminergic neurotransmission and thereby improving motor function in Parkinson's disease.

Apomorphine may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: transient feeling of sickness often occurring shortly after dosing.
• Dizziness: light‑headedness that may be related to orthostatic changes.
• Orthostatic hypotension: drop in blood pressure upon standing, leading to faintness.
• Headache: mild to moderate pain often resolving with continued therapy.
• Somnolence: increased sleepiness or fatigue during the day.
• Dry mouth: reduced salivation causing discomfort.

Serious or Rare Side Effects

• Severe hypotension: marked blood‑pressure decline requiring medical intervention.
• Syncope: sudden loss of consciousness associated with blood‑pressure changes.
• Hallucinations: visual or auditory disturbances that may affect safety.
• Impulse‑control disorders: compulsive behaviors such as gambling or hypersexuality.
• Cardiac arrhythmias: irregular heart rhythms that can be life‑threatening.
• Persistent vomiting: prolonged emesis leading to dehydration and electrolyte imbalance.

When prescribing Kynmobi, clinicians should consider several safety measures.

• Assess cardiovascular status: monitor blood pressure and heart rate before and during therapy.
• Review concomitant medications: avoid co‑administration with MAO‑B inhibitors to prevent hypertensive crisis.
• Evaluate for impulse‑control disorders: monitor patients for emerging compulsive behaviors.
• Consider hepatic and renal function: adjust use in patients with significant impairment.
• Avoid use in individuals with known hypersensitivity to apomorphine or excipients.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Apomorphine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• MAO‑B inhibitors: risk of hypertensive crisis when combined.
• Antipsychotics (D2 antagonists): may diminish apomorphine efficacy.
• Other dopamine agonists: additive dopaminergic effects increasing side‑effect risk.

Moderate Interactions (Monitor Closely)

• Antihypertensives: potential enhancement of orthostatic hypotension.
• SSRIs/SNRIs: may increase nausea and dizziness.
• Alcohol: can amplify sedation and hypotensive effects.